|
|
Stephanie
Land, PhD
Research
Assistant Professor
Education
BS, University
of Texas at Austin
MS, University of Texas at Austin
PhD, Stanford University
Research Interests
My
current research is in two areas: 1) behavioral research related
to smoking, and 2) the development and application of statistical
methodology to cancer clinical trials, primarily in lung cancer,
breast cancer, and colorectal cancer. I am the Executive Director
for
The Reduce Smoking and Exposure to Tobacco (ReSET) Center. I
am also the statistician responsible for the
Behavioral and Health Outcomes Program at the National Surgical
Adjuvant Breast and Bowel Project (NSABP). (Health
Sciences Faculty Research Interests Project). I am an Associate
Editor for the Journal of Clinical Oncology and Consulting Editor
for the Annals of Surgical Oncology.
Selected Publications
(June 2006-Present)
Land,
S.R., D.L. Wickerham, J.P. Costantino, M.W. Ritter, V.G. Vogel,
M. Lee, E.R. Pajon, J.L. Wade, 3rd, S. Dakhil, J.B. Lockhart, Jr.,
N. Wolmark, and P.A. Ganz, Patient-reported symptoms and quality
of life during treatment with tamoxifen or raloxifene for breast
cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR)
P-2 trial. Journal of the American Medical Association, 2006
Jun 21. 295(23): p. 2742-51.
Land, S.R., L.
Wickerham, J.P. Costantino, M.W. Ritter, V.G. Vogel, M. Lee, E.R.
Pajon, J.L.I. Wade, S. Dakhil, J.B.J. Lockhart, N. Wolmark, and
P.A. Ganz, The Study of Tamoxifen and Raloxifene: Brief Review of
Patient-Reported Outcomes From the National Surgical Adjuvant Breast
and Bowel Project P-2 Breast Cancer Prevention Study. The American
Journal of Hematology/Oncology, 2006. 5: Supplement(9): p. 23-27.
Moschos, S.J.,
H.D. Edington, S.R. Land, U.N. Rao, D. Jukic, J. Shipe-Spotloe,
and J.M. Kirkwood, Neoadjuvant treatment of regional stage IIIB
melanoma with high-dose interferon alfa-2b induces objective tumor
regression in association with modulation of tumor infiltrating
host cellular immune responses. J Clin Oncol, 2006 Jul 1.
24(19): p. 3164-71.
Stabile, L.P.,
J.S. Lyker, S.R. Land, S. Dacic, B.A. Zamboni, and J.M. Siegfried,
Transgenic mice overexpressing hepatocyte growth factor in the airways
show increased susceptibility to lung cancer. Carcinogenesis,
2006 Aug. 27(8): p. 1547-55.
Kopec, J.A., S.R.
Land, R.S. Cecchini, P.A. Ganz, D. Cella, J.P. Costantino, H.S.
Wieand, R.E. Smith, J.P. Kuebler, and N. Wolmark, Validation of
a self-reported neurotoxicity scale in patients with operable colon
cancer receiving oxaliplatin. Journal of Supportive Oncology,
2006 Sept. 4(8): p. W1-W8.
Primack, B.A.,
M.A. Gold, S.R. Land, and M.J. Fine, Association of cigarette smoking
and media literacy about smoking among adolescents. J Adolesc
Health, 2006 Oct. 39(4): p. 465-72.
Julian, T.B.,
S.R. Land, V. Fourchotte, S.R. Haile, E.R. Fisher, E.P. Mamounas,
J.P. Costantino, and N. Wolmark, Is Sentinel Node Biopsy Necessary
in Conservatively Treated DCIS? Ann Surg Oncol, 2007 May
30.
Kopec, J.A., G.
Yothers, P.A. Ganz, S.R. Land, R.S. Cecchini, H.S. Wieand, B.C.
Lembersky, and N. Wolmark, Quality of life in operable colon cancer
patients receiving oral compared with intravenous chemotherapy:
results from National Surgical Adjuvant Breast and Bowel Project
Trial C-06. J Clin Oncol, 2007 Feb 1. 25(4): p. 424-30.
Land, S.R., J.A.
Kopec, R.S. Cecchini, P.A. Ganz, H.S. Wieand, L.H. Colangelo, K.
Murphy, J.P. Kuebler, T.E. Seay, B.M. Needles, J.D. Bearden, 3rd,
L.K. Colman, K.S. Lanier, E.R. Pajon, Jr., D. Cella, R.E. Smith,
J. O'Connell M, J.P. Costantino, and N. Wolmark, Neurotoxicity From
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin
As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer:
NSABP C-07. J Clin Oncol, 2007 June 1. 25(16).
Moschos, S.J.,
C. Odoux, S.R. Land, S. Agarwala, D. Friedland, K.M. Volker, C.
Sidor, M. Wong, and J.M. Kirkwood, Endostatin plus interferon-alpha2b
therapy for metastatic melanoma: a novel combination of antiangiogenic
and immunomodulatory agents. Melanoma Res, 2007 Jun. 17(3):
p. 193-200.
Wang, W., H.D.
Edington, U.N. Rao, D.M. Jukic, S.R. Land, S. Ferrone, and J.M.
Kirkwood, Modulation of signal transducers and activators of transcription
1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer
Res, 2007 Mar 1. 13(5): p. 1523-31.
Zhang, W., J.L.
Weissfeld, M. Romkes, S.R. Land, J.R. Grandis, and J.M. Siegfried,
Association of the EGFR intron 1 CA repeat length with lung cancer
risk. Mol Carcinog, 2007 May. 46(5): p. 372-80.
Deutsch, M., S.R.
Land, M. Begovic, R. Cecchini, and N. Wolmark, An association between
postoperative radiotherapy for primary breast cancer in 11 National
Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the
subsequent appearance of pleural mesothelioma. Am J Clin Oncol,
2007 Jun. 30(3): p. 294-6.
Fisher, E.R.,
S.R. Land, R.S. Saad, B. Fisher, D.L. Wickerham, M. Wang, J.P. Costantino,
and N. Wolmark, Pathologic variables predictive of breast events
in patients with ductal carcinoma in situ. Am J Clin Pathol, 2007
Jul. 128(1): p. 86-91.
Primack, B.A.,
J.E. Bost, S.R. Land, and M.J. Fine, Volume of tobacco advertising
in African American markets: systematic review and meta-analysis.
Public Health Rep, 2007 Sep-Oct. 122(5): p. 607-15.
Moinpour, C.M.,
A. Denicoff, D. Watkins-Bruner, A.B. Kornblith, S. Land, A.M. O'Mara,
and E.L. Trimble, Special series (PROACT): Funding patient-reported
outcomes (PROs) in cancer clinical trials. Journal of Clinical
Oncology, (In Press).
Land SR, Ritter
MW, Costantino JP, Julian TB, Cronin WM, Haile SR, Wolmark N, and
Ganz PA, “Special Series (PROACT): Compliance With Patient-Reported
Outcomes in Multi-Center Clinical Trials: Methodological And Practical
Approaches,” J Clin Oncol. (In Press)
Bhatnagar A.K.,
Land S.R., Shogan A., Rodgers E., Heron D.E., Flickinger, J.C. What
do patients want from their radiation oncologist: initial results
from a prospective trial, International Journal of Radiation
Oncology, Biology, Physics. (In Press)
Cella, D., S.R.
Land, C. Chang, R. Day, J.P. Costantino, N. Wolmark, P. Ganz, Symptom
measurement in the breast cancer prevention trial (BCPT) (P-1):
psychometric properties of a new measure of symptoms for midlife
women, Breast Cancer Research and Treatment. (In Press)
Mamounas EF, Jeong
J, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher
L, Farrar W, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins
LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE, Costantino JP, and
Wolmark N. Benefit from Exemestane as Extended Adjuvant Therapy
Following Five Years of Adjuvant Tamoxifen: Intent-to-Treat Analysis
of the National Surgical Adjuvant Breast and Bowel Project B-33
Trial, J Clin Oncol. (In Press)
Contact Information
One Sterling
Plaza
201 North Craig Street, Suite 350
Pittsburgh, PA 15213
Telephone: 412-383-2213
Facsimile: 412-383-1387
Email: Land at nsabp.pitt.edu
|
 |
